Function and clinical meaningfulness of treatments for mild Alzheimer's disease

por Siemers, Eric, Holdridge, Karen Chilcott, Sundell, Karen L., Liu-Seifert, Hong
Publicado 2016

A Novel Approach to Delayed-Start Analyses for Demonstrating Disease-Modifying Effects in Alzheimer’s Disease

por Liu-Seifert, Hong, Andersen, Scott W., Lipkovich, Ilya, Holdridge, Karen C., Siemers, Eric
Publicado 2015

Magnetic resonance imaging measures of brain volumes across the EXPEDITION trials in mild and moderate Alzheimer's disease dementia

por Svaldi, Diana Otero, Higgins, Ixavier A., Holdridge, Karen C., Yaari, Roy, Case, Michael, Bracoud, Luc, Scott, David, Shcherbinin, Sergey, Sims, John R.
Publicado 2022

Delayed-start analysis: Mild Alzheimer's disease patients in solanezumab trials, 3.5 years

por Liu-Seifert, Hong, Siemers, Eric, Holdridge, Karen C., Andersen, Scott W., Lipkovich, Ilya, Carlson, Christopher, Sethuraman, Gopalan, Hoog, Sharon, Hayduk, Roza, Doody, Rachelle, Aisen, Paul
Publicado 2015

Central pharmacodynamic activity of solanezumab in mild Alzheimer's disease dementia

por Willis, Brian A., Sundell, Karen, Lachno, D. Richard, Ferguson-Sells, Lisa R., Case, Michael G., Holdridge, Karen, DeMattos, Ronald B., Raskin, Joel, Siemers, Eric R., Dean, Robert A.
Publicado 2018

Avoid or Embrace? Practice Effects in Alzheimer’s Disease Prevention Trials

por Aschenbrenner, Andrew J., Hassenstab, Jason, Wang, Guoqiao, Li, Yan, Xiong, Chengjie, McDade, Eric, Clifford, David B., Salloway, Stephen, Farlow, Martin, Yaari, Roy, Cheng, Eden Y. J., Holdridge, Karen C., Mummery, Catherine J., Masters, Colin L., Hsiung, Ging-Yuek, Surti, Ghulam, Day, Gregory S., Weintraub, Sandra, Honig, Lawrence S., Galvin, James E., Ringman, John M., Brooks, William S., Fox, Nick C., Snyder, Peter J., Suzuki, Kazushi, Shimada, Hiroyuki, Gräber, Susanne, Bateman, Randall J.
Publicado 2022

Evaluation of dose‐dependent treatment effects after mid‐trial dose escalation in biomarker, clinical, and cognitive outcomes for gantenerumab or solanezumab in dominantly inherite...

por Wang, Guoqiao, Li, Yan, Xiong, Chengjie, McDade, Eric, Clifford, David B., Mills, Susan L., Santacruz, Anna M., Aschenbrenner, Andrew J., Hassenstab, Jason, Benzinger, Tammie L.S., Gordon, Brian A., Fagan, Anne M., Coalier, Kelley A., Libre‐Guerra, Jorge J., McCullough, Austin, Joseph‐Mathurin, Nelly, Chen, Charles D., Mummery, Catherine, Wendelberger, Barbara A., Gauthier, Serge, Masellis, Mario, Holdridge, Karen C., Yaari, Roy, Chatterjee, Saptarshi, Sims, John, Delmar, Paul, Kerchner, Geoffrey A., Bittner, Tobias, Hofmann, Carsten, Bateman, Randall J.
Publicado 2022

Amyloid‐Related Imaging Abnormalities in the DIAN‐TU‐001 Trial of Gantenerumab and Solanezumab: Lessons from a Trial in Dominantly Inherited Alzheimer Disease

por Joseph‐Mathurin, Nelly, Llibre‐Guerra, Jorge J., Li, Yan, McCullough, Austin A., Hofmann, Carsten, Wojtowicz, Jakub, Park, Ethan, Wang, Guoqiao, Preboske, Gregory M., Wang, Qing, Gordon, Brian A., Chen, Charles D., Flores, Shaney, Aggarwal, Neelum T., Berman, Sarah B., Bird, Thomas D., Black, Sandra E., Borowski, Bret, Brooks, William S., Chhatwal, Jasmeer P., Clarnette, Roger, Cruchaga, Carlos, Fagan, Anne M., Farlow, Martin, Fox, Nick C., Gauthier, Serge, Hassenstab, Jason, Hobbs, Diana A., Holdridge, Karen C., Honig, Lawrence S., Hornbeck, Russ C., Hsiung, Ging‐Yuek R., Jack, Clifford R., Jimenez‐Velazquez, Ivonne Z., Jucker, Mathias, Klein, Gregory, Levin, Johannes, Mancini, Michele, Masellis, Mario, McKay, Nicole S., Mummery, Catherine J., Ringman, John M., Shimada, Hiroyuki, Snider, B. Joy, Suzuki, Kazushi, Wallon, David, Xiong, Chengjie, Yaari, Roy, McDade, Eric, Perrin, Richard J., Bateman, Randall J., Salloway, Stephen P., Benzinger, Tammie L.S., Clifford, David B.
Publicado 2022